SLC

DECEMBER 2018

TICKER: 4167

DISCLAIMER

This presentation has been provided by Savior Lifetec Corporation (SLC) for informational purposes only. It is not an offer to buy or sell or a solicitation of an offer to buy or sell any security issued by SLC or other parties.

This presentation may contain forward-looking statements which reflect SLC management's views, estimates, and currently available information. These statements are SLC management's opinion and SLC does not provide warranty for the accuracy, reliability, and completeness of the information. Investors should not place undue reliance on the statements, as there are significant risks that could cause actual results or future developments to differ materially from those expressed or implied by forward looking statements. Potential risks include economic conditions, foreign exchange fluctuations, competitive product and pricing pressures, and regulatory developments.

SLC has no obligation to update any forward-looking statement or figures, whether as a result of new information, future events, or otherwise.

About Savior

- Current Products and Products in Development
  - Penem Injectables
  - Non-Penem Injectables
  - CDMO
- Company Scale
  - ~550 Employees
  - 2017 Annual Revenues NT$1.5bn
- Industry Leadership
  - Top 3 Global Penem Supplier
  - One of Leading Suppliers of Meropenem
  - Taiwan's Largest Injectable Supplier by US Sales
  - Amongst the Few Drug Manufacturers Compliant With US/EU/JP GMP
    (Fewer Than 10 Out Of 113 Taiwan Manufacturers)

Memorabilia

Signed a new drug development contract



Savior Strategy

Stages 1 and 2 have been completed. SLC is making progress in Stages 3 and 4



Enablers					
	Reverse Engineering	Quality Infrastructure	Vertical Integration	Complex Chemistry	R&D Expertise
	Low Cost Structure	Vertical Integration	Regulatory Expertise		

New Manager

Experience in the most famous pharmaceutical companies in Taiwan

Title	Name	Experience
General Manager	Yung Fa Chen	President &CEO, Chief Technology Officer of ScinoPharm ,Ltd. Adjunct associate professor at Tunghai University Department of Chemistry Project manager at the Refining & Manufacturing Research Institute of CPC Corp., Taiwan.
Assistant Manager	Lung Huang Kuo	Senior Director of ScinoPharm ,Ltd. manager of Synthesis Department , Standard Chem. & Pharm. Co. Postdoctoral research in chemistry, Ohio State University; director of Synthesis Research Institute at Sinon Corp.
Assistant Manager	Yu Wen Lo	Senior manager of regulations of ScinoPharm ,Ltd.

Note： Yung Fa Chen arrived on December 3, 2018. It is expected that the board of directors will ratify it on December 28, 2018.

Agenda

Operating Overview

Meropenem

Ertapenem

New Antibiotics

Operating Overview

3Q18 Income statement

($mn)	3Q18	2Q18	Q317
Net Sales	261	313	389
COGS	305	310	277
Gross Profit	(44)	3	112
Gross Margin	(17%)	1%	29%
Operating Expense	48	67	90
Operating Income	(92)	(64)	22
Operating Margin	(35%)	(21%)	(2%)
Non-Op Income (Expense)	(4)	11	(5)
Net Income	(96)	(52)	17
Net Margin	(37%)	(17%)	4%
EPS	(0.39)	(0.21)	0.07
Cash & Cash Equivalents	423	512	423

Vision at 2019

- Meropenem Supply shortage in the United States
- Research service for pre-production process validation of antibiotic new drug products in cooperation with Global pharmaceutical companies
- Cooperating with Global pharmaceutical companies to jointly invest in the construction of oral pharmaceutical factory

Meropenem

Meropenem continues to grow

CAGR 3%



Source: IMS

US market trend

More than half of US suppliers have a shortage of supply

According to the ASHP news on 2018/12/7 , Meropenem Injectable have a shortage of supply

Marketer	ANDA	Approval Year	ANDA#	ASHP (Affected)
Pfizer/Hospira	Hospira	2010	#090940	**Yes**
Fresenius Kabi	ACS Dobfar	2011	#091404	
Sagent	Daewoong	2015	#204854	**Yes**
Amneal	Amneal	2016	#205883	**Yes**
Sandoz	SLC	2016	#206086	
AuroMedics	Aurobindo	2017	#205835	**Yes**

There are 4 / 6 manufacturers of injection products affected.

Source: American Society of Health-System Pharmacists

Ertapenem

Ertapenem MA

- UK Ertapenem MA approved
- Will soon obtain major market drug certificates



Source: IMS

New Antibiotics

New Drug Development Partnership Will Drive Revenue Growth

Savior is well positioned to collaborate with antibiotic developers

Savior and Global pharmaceutical continued to sign a new drug prenatal process validation service contract on 2018/06/07.

- Process validation service revenue will be recognized in the future.

Savior and Global pharmaceutical signed to build an oral drug factory contract on 2018/11/26

- Will sign a new drug-related research and development cooperation case.
- New drug is launched, Savior will be responsible for the production of oral tablets.

In The Past Few Decades, Antibiotic Approvals Have Declined

This is due to technological, financial, and regulatory hurdles



Source: US FDA

QUALIFIED INFECTIOUS DISEASE STATUS

>100 new antibiotic development case obtained QIDP qualification(Admission rate of 90%)

QIDP Advantages

Exclusivity	QIDP drugs receive an additional 5 years exclusivity. For instance, if an NCE was entitled to 5 years of exclusivity under Hatch Waxman, if the drug received QIDP status, it would receive 10 years of exclusivity.
Priority Review	The FDA would decrease the target review time from 10 months to 6 months.
Fast Track	The FDA would increase communications, allow partial reviews.

THE 8 APPROVED QIDP ANTIBIOTICS

Source: US Government Accountability Office Report Jan-2017

Antibiotic Resistance Continues to Trend Higher



- Quinolone and Cephalosporin Efficacy Steadily Eroding.

Source: Center for Disease Dynamics, Economics Policy (CDDEP) & The Surveillance Network (TSN); Gonzalo Bearman MD,MPH; Centers for Disease Control (CDC)
(1) FDA warns against the use of quinolones for uUTI due to safety concerns

Quinolone Resistance Driving Need for New Therapies

2014, CDC, inpatient E. coli Quinolone resistance, by state



2017 outpatient Enterobacteriaceae Quinolone Resistance, by zip code



>25% resistance rate in most populous regions of the U.S.

Why is Oral Specialty Antibiotic Different

Challenges Faced by Recent Antibiotic Launches	Oral Special Antibiotic Differentiation
IV Only Antibiotics Limited hospital market with inexpensive generic competitors	**Oral Antibiotic** • Access to very large community market with Oral Specialty Antibiotic • Opportunity for step-down to Oral Specialty Antibiotic to reduce hospital length-of-stay and/or confidently transition home
Hospital Focused • Long & challenging formulary process • Reimbursed within existing DRG	**Community Focused, plus Hospital Step-Down** • Favorable reimbursement with Oral Specialty Antibiotic • Reimbursement for Oral Specialty Antibiotic not part of the DRG
Single Indication Products focus on a single indication, often with niche markets	**Multiple Indications at Launch** Oral Specialty Antibiotic to launch with several indications.
Unproven and Challenging Antibiotic Classes New antibiotic classes or antibiotic classes with known safety challenges	**Proven & Trusted Antibiotic Class** • Safe with efficacy and trust of a Antibiotic • Potential to be the first oral Specialty Antibiotic available in the U.S.
Fierce Competition Multiple branded products fighting for share in small hospital IV markets	**Dominant Share of Voice** • First new branded oral for UTIs in over 20 years • Potential to be only product promoted for UTI for a few years post approval

Great Potential for Oral Specialty Antibiotic

Benefit of Oral Specialty Antibiotic

Community patients to avoid hospitalization

Hospitalized patients to shorten length of hospital stay

US Market Opportunity Overview

Market Segment	Total Patients	FQ-R*	LOT	Market Opportunity
Community UTI FQ-Resistant	10.2M	12%	5.5 Days	$ 2.3 Billion
Hospital UIT FQ-Resistant	2.2M	35%	7 Days	$ 1.9 Billion
Hospital "Other" FQ-Resistant	1.1M	35%	7 Days	$ 900 Million

Source: Estimates derived primarily from QuintilesIMS market assessment (August+2017); *Resistance estimates directly from market assessment
FQ: Fluoroquinolone

Q&A